Abstract
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
Highlights
Nowadays, hepatitis C virus (HCV) infection represents a global health problem, affecting over 160 million people worldwide[1]
The efforts to improve the hepatitis C management resulted in the discovery and development of directacting antivirals (DAAs), which are meant to interfere with specific steps in HCV replication; in other words, they directly interact with HCV encoded proteins, resulting in the disruption of viral replication[5]
This study aims to assess the effect of DAAs on liver function and to analyze the particularities of hepatocellular carcinoma (HCC) diagnosed during or after treatment with Paritaprevir/Ombistasvir/Ritonavir and Dasabuvir with or without ribavirin
Summary
Hepatitis C virus (HCV) infection represents a global health problem, affecting over 160 million people worldwide[1]. There is evidence that 2.8%11.7% of the patients with compensated LC will develop hepatic decompensation sooner or later; as for the incidence of HCC, a percentage of 1.8%-8.3% has been reported[3]. The use of pegylated interferon (IFN) in combination with ribavirin, in treating the HCV infection, leads to a sustained virological response (SVR) in about 50% of patients and it is known to have significant side effects[4]. The efforts to improve the hepatitis C management resulted in the discovery and development of directacting antivirals (DAAs), which are meant to interfere with specific steps in HCV replication; in other words, they directly interact with HCV encoded proteins, resulting in the disruption of viral replication[5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
